Mainz Biomed NV has announced that its pancreatic cancer project will receive public funding from the Investitions- und Strukturbank Rheinland-Pfalz (ISB), the development bank of the German federal state of Rheinland-Pfalz. Under the ISB's Innovation and Technology Support Program, the state will fund up to 50% of the project's total costs. This governmental support highlights the scientific and societal value of the company's non-invasive, blood-based screening test for early pancreatic cancer detection, and is expected to accelerate its development. The funding is specifically for Mainz Biomed, and there is no indication of multiple organizations receiving this grant.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: corporate_2169898_en), on July 15, 2025, and is solely responsible for the information contained therein.